Navigation Links
Reliance Pharmaceuticals: Biosimilars Company Analysis

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:


Reliance Pharmaceuticals: Biosimilars Company Analysis


This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.Reliance Life Sciences has a primary focus on biopharmaceuticals and pharmaceuticals, but also a presence in the wider areas of clinical research services, regenerative medicine, molecular medicine, and biofuels. The overall sales of Reliance Life Sciences totaled $104.7m in FY2011, with approximately 70% coming from biopharmaceutical products.Assess Reliance's portfolio of 7 marketed biosimilars and 20 pipeline products, which includes 3 monoclonal antibody productsSee how the 2007 acquisition of GeneMedix will help diversify Reliance's geographical focus




ABOUT THIS REPORT•Chapter structure - Strategic insight

- Product analysis

- Corporate structure


•Data sourcing

•PharmaVitae Explorer database


EXECUTIVE SUMMARY•Reliance Life Sciences biosimilars overview

•Reliance Life Sciences biosimilars infrastructure


STRATEGIC INSIGHT•Reliance Life Sciences made the strategic acquisition of GeneMedix to penetrate the European markets

•Reliance is focusing on the oncology therapy area and developing a portfolio of MAb biosimilars - Oncology focus


•Reliance Life Sciences biosimilars SWOT analysis - Strengths

- Weaknesses

- Opportunities

- Threats



KEY PRODUCTS•Reliance Life Sciences biosimilars portfolio

•ReliPoietin (epoetin alfa) - Overview

- Erythropoietin market size

- Key competitors


•ReliGrast (filgrastim)Reliance Life Sciences launched biosimilar granulocyte colony-stimulating factor (GCSF) ReliGrast in 2008. It is currently marketed in India and other semi-regulated markets. - Filgrastim and pegfilgrastim market size

- Key competitors


•ReliFeron (interferon alfa-2b) - Overview

- Interferon alfa market size

- Key competitors


•FostiRel (follitropin beta) - Market overview

- Key competitors


•ReliBeta (interferon beta-1a) - Overview

- Interferon beta market size

- Key competitors

- Reliance Life Sciences' other marketed products and biosimilar development




•Key corporate developments

•Company structure - Biopharmaceuticals

- Novel therapeutics

- Pharmaceuticals

- Clinical research services

- Regenerative medicine

- Molecular medicine

- Plant biotechnology

- Industrial biotechnology


•Deals and alliances

•Recent developments


APPENDIX•References - Datamonitor reports


•Exchange rates




•Table: Reliance Life Sciences biosimilars development and marketing capabilities

•Table: Forecast global sales of infliximab, rituximab, and abciximab ($m), 2011–16

•Table: Reliance Life Sciences – life sciences initiatives

•Table: Reliance Life Sciences – biosimilar/copy-biologic portfolio

•Table: Forecast epoetin sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic epoetin and darbepoetin drugs

•Table: Forecast filgrastim and pegfilgrastim sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs

•Table: Forecast interferon alfa and peginterferon alfa sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon alfa

•Table: Forecast follitropin alfa and beta sales in the seven major markets ($m), 2011–16

•Table: Biosimilar/copy-biologic follitropin drugs, 2012

•Table: Forecast interferon beta sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon beta drugs

•Table: Reliance Life Sciences – monoclonal antibodies under development

•Table: Reliance Life Sciences/GeneMedix deal activity and biosimilar deals, 2000?12

•Table: Exchange rates, 2012




•Figure: The PharmaVitae Explorer

•Figure: Reliance Life Sciences biosimilars overview

•Figure: Mutual benefits through Reliance Life Sciences' acquisition of GeneMedix

•Figure: Reliance Life Sciences – biosimilar and pharmaceutical products and therapy area

•Figure: Reliance Life Sciences SWOT analysis

•Figure: Proportion of government and private health expenditure versus personal disposable income, in India and other major markets, 2009

•Figure: Reliance Life Sciences – revenues, FY2010–12

•Figure: Reliance Life Sciences – revenues, FY2010?12

•Figure: Reliance Life Sciences – company structure




Companies Mentioned

Antares Pharma, Inc., Asian Development Bank, CJ Corporation, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Reliance Industries Limited, Schindler Holding Ltd.




To order this report:

Biopharmaceutical Industry: Reliance Pharmaceuticals: Biosimilars Company Analysis


Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626


SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceuticals: Global Industry Almanac, MarketLine
2. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
3. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
6. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
7. Donor Alliance Named Colorados Top Healthcare Company
8. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
9. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
10. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, while ... light of the recent terrorist attacks in Paris, other cities are taking extra precautions ... reaching U.S. soil. Especially around special events that may be high-profile in nature, the ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I ... an inventor from Hillside, N.J. "Many people catch diseases simply from sitting on ... will always be protected from germs." , He developed the patent-pending QUDRATECS to ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of ... in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately ... nationally, through a vast social media strategy and across a network of top ...
(Date:11/27/2015)... , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the ... Table 1-1 ). More than 3.7 billion people under the age of 50 ... (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The data ...
Breaking Medicine News(10 mins):